scholarly journals Prognostic value of staging FDG PET/CT in patients with metastatic colorectal cancer

2018 ◽  
Vol 29 ◽  
pp. ix42-ix43
Author(s):  
E.K. Choi ◽  
J.K. Oh ◽  
Y.-A. Chung
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals The Prognostic Value of SUVmax of 18F-FDG PET/CT in Patients with Metastatic Colorectal Cancer

2020 ◽  
Vol 49 (1) ◽  
pp. 1
Author(s):  
Emir Sokolović ◽  
Timur Cerić ◽  
Šejla Cerić ◽  
Semir Bešlija ◽  
Sandra Vegar-Zubović ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Disease Progression ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Prognostic Markers ◽  
Pet Ct ◽  
Ct Analysis ◽  
18F Fdg ◽  
Fdg Pet Ct

<p><strong>Objective. </strong>The aim of the study was to evaluate the prognostic value of the maximum standardized uptake value (SUVmax) of 18F-Fluorodeoxyglucose (18F-FDG) PET/CT in patients with metastatic colorectal cancer, and to compare it with classical prognostic markers.</p><p><strong>Materials and Methods. </strong>The study included 70 patients with metastatic colorectal cancer who had not been treated for the metastatic disease. The patients underwent 18F-FDG PET/CT as part of their routine diagnostic reevaluation. During the analysis, the value of the largest tumor diameter and SUVmax was determined for the lesion with the highest SUVmax observed. The values of CEA and CA 19-9 were recorded 7 days before the PET/CT analysis.</p><p><strong>Results. </strong>SUVmax and Carbohydrate antigen (CA)19-9 were found to be independent prognostic markers of disease progression within 12 months. Based on the Receiver Operating Characteristics (ROC) curve analysis, the patients could be divided into two groups: SUVmax≤4.1 vs. SUVmax&gt;4.1. Patients with SUVmax values of 4.1 or less had significantly better progression-free survival within 12 months with an HR (95% CI) of 2.97 (1.4-6.3), relative to patients with SUVmax values above 4.1.</p><p><strong>Conclusion. </strong>SUVmax may be used as a novel prognostic marker of disease progression among patients with metastatic colorectal cancer. Values of SUVmax can be used to select patients with a more aggressive type of disease and higher risk for progression within 12 months of PET/CT analysis.</p>

Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer

2011 ◽  
Vol 66 (12) ◽  
pp. 1167-1174 ◽  
Author(s):  
R.H. Briggs ◽  
F.U. Chowdhury ◽  
J.P.A. Lodge ◽  
A.F. Scarsbrook
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Fdg Pet ◽  
Clinical Impact ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Serial FDG–PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy

2012 ◽  
Vol 23 (7) ◽  
pp. 1687-1693 ◽  
Author(s):  
A. Hendlisz ◽  
V. Golfinopoulos ◽  
C. Garcia ◽  
A. Covas ◽  
P. Emonts ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Fdg Pet ◽  
Outcome Prediction ◽  
Early Outcome ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Usefulness of 18F-FDG PET/CT, LDH and tumor markers in the prognosis and evaluation of tumor response after RMB therapy in advanced, metastatic colorectal cancer (mCRC)

2017 ◽  
Vol 28 ◽  
pp. iii12
Author(s):  
Angelica Nazarian ◽  
Zoe Andrada ◽  
Joanne Thomas ◽  
Sudipta Sureshbabu ◽  
Nathaniel Berman ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Tumor Markers ◽  
Fdg Pet ◽  
Tumor Response ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Retrospective analysis of the prognostic value of PD-L1 expression and 18F-FDG PET/CT metabolic parameters in colorectal cancer

2020 ◽  
Vol 11 (10) ◽  
pp. 2864-2873 ◽  
Author(s):  
Hao Jiang ◽  
Rongjun Zhang ◽  
Huijie Jiang ◽  
Mingyu Zhang ◽  
Wei Guo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Retrospective Analysis ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Metabolic Parameters ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Preoperative PET/CT 18F-FDG Standardized Uptake by Lymph Nodes as a Significant Prognostic Factor in Patients with Colorectal Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Ruohua Chen ◽  
Yining Wang ◽  
Xiang Zhou ◽  
Gang Huang ◽  
Jianjun Liu
Keyword(s):  
Colorectal Cancer ◽  
Lymph Nodes ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Treatment Modalities ◽  
Significant Prognostic Factor ◽  
Tumour Grade ◽  
Characteristic Analysis ◽  
Pet Ct ◽  
Fdg Pet Ct

Purpose. We evaluated the prognostic value of preoperative 18F-FDG uptake by suspected lymph nodes (LNs) using 18F-FDG PET/CT in colorectal cancer patients. Methods. Patients with CRC underwent 18F-FDG PET/CT before radical surgery. We used Cox proportional hazards regression to examine the relationship between recurrence and the 18F-FDG maximum standardized uptake value (SUVmax) in the suspected LNs (SUVLN) on 18F-FDG PET/CT. Results. Clinical data, treatment modalities, and results from 90 CR C patients were reviewed. The median follow-up was 19 months (range 3 to 72 months). Receiver operating characteristic analysis identified SUVLN 1.15 was the optimal cut-off value for predicting recurrence. SUVLN correlated with tumour size (P=0.045), lymph node metastasis (P=0.03), and recurrence (P<0.0001). Univariate analysis showed significant associations between recurrence and SUVLN (P=0.017), and tumour grade (P=0.013). Multivariate analysis identified SUVLN (P<0.0001), and tumour grade (P=0.005) as independent risk factors for recurrence. Patients with SUVLN ≤ 1.15 and SUVLN > 0.15 differed significantly in terms of recurrence (P<0.0001). Conclusion. Preoperative SUVLN measured by 18F-FDG PET/CT was significantly associated with recurrence and had significant prognostic value for recurrence-free survival in patients with colorectal cancer.

scholarly journals Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer

2020 ◽  
Vol 26 (4) ◽  
pp. 2683-2691
Author(s):  
Zsuzsanna Nemeth ◽  
Wouter Wijker ◽  
Zsolt Lengyel ◽  
Erika Hitre ◽  
Katalin Borbely
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Metastatic Colorectal Cancer ◽  
Metabolic Activity ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Metabolic Parameters ◽  
First Line ◽  
Pet Ct ◽  
Fdg Pet Ct

AbstractWe tested the prognostic relevance of metabolic parameters and their relative changes in patients with metastatic colorectal cancer (mCRC) treated with monoclonal antibody and chemotherapy. SUVmax (standardized uptake volume), SAM (standardized added metabolic activity) and TLG (total lesion glycolysis) are assessed with 18F-fluorodeoxyglucosepositron emission tomography and computed tomography (FDG-PET/CT) to evaluate total metabolic activity of malignant processes. Our purpose was to investigate the change of glucose metabolism in relation to PFS (progression free survival) and OS (overall survival). Fifty-three patients with mCRC with at least one measurable liver metastasis were included in this prospective, multi-center, early exploratory study. All patients were treated with first-line chemotherapy and targeted therapy. Metabolic parameters, like SUVmax, SAM, normalized SAM (NSAM) and TLG were assessed by FDG-PET/CT, carried out at baseline (scan-1) and after two therapeutic cycle (scan-2). Our results suggested neither SUVmax nor TLG have such prognostic value as NSAM in liver metastases of colorectal cancer. The parameters after the two cycles of chemotherapy proved to be better predictors of the clinical outcome. NSAM after two cycles of treatment has a statistically significant predictive value on OS, while SAM was predictive to the PFS. The follow up normalized SAM after 2 cycles of first line oncotherapy was demonstrated to be useful as prognostic biomarkers for OS in metastatic colorectal cancer. We should introduce this measurement in metastatic colorectal cancer if there is at least one metastasis in the liver.

Sign in / Sign up

Export Citation Format

Share Document